Relative drug sensitivites and cholesterol and RNA assays performed with samples from AML patients
AML sample . | Relative Via + DNR . | Relative Via + ARA-C . | Chol . | Semi-Q RT-PCR . | Quant RT-PCR . |
|---|---|---|---|---|---|
| Adult 1 | 1.05 | 1.00 | x | ND | ND |
| Adult 2 | 0.89 | 0.91 | x | ND | ND |
| Adult 3 | 1.01 | 1.04 | x | x | x |
| Adult 4 | 0.92 | 0.95 | x | ND | ND |
| Adult 5 | 0.86 | 0.87 | x | x | x |
| Adult 6 | 0.95 | 0.84* | x | x | x |
| Adult 7 | 0.98 | 0.99 | x | x | x |
| Adult 8 | 0.88 | 1.01 | x | x | x |
| Adult 9 | 0.81* | 1.07 | x | x | x |
| Adult 10 | 0.97 | 0.94 | x | ND | ND |
| Adult 11 | 0.79* | 0.92 | x | x | x |
| Adult 12 | 0.90 | 1.00 | ND | x | x |
| Adult 13 | 0.97 | 0.97 | x | x | x |
| Pediatric 1 | 0.93 | 1.03 | x | x | x |
| Pediatric 2 | 0.99 | 1.01 | x | x | x |
| Pediatric 3 | 0.88 | 0.94 | x | x | ND |
| Pediatric 4 | 1.00 | 0.91 | x | x | x |
| Pediatric 5 | 1.00 | 0.91 | x | x | x |
| Pediatric 6 | 0.94 | 1.00 | x | x | x |
| Pediatric 7 | 0.83* | 0.88 | x | ND | ND |
| No. | 20 | 20 | 19 | 15 | 14 |
| Mean | 0.92 | 0.96 | — | — | — |
| SEM | 0.02 | 0.01 | — | — | — |
AML sample . | Relative Via + DNR . | Relative Via + ARA-C . | Chol . | Semi-Q RT-PCR . | Quant RT-PCR . |
|---|---|---|---|---|---|
| Adult 1 | 1.05 | 1.00 | x | ND | ND |
| Adult 2 | 0.89 | 0.91 | x | ND | ND |
| Adult 3 | 1.01 | 1.04 | x | x | x |
| Adult 4 | 0.92 | 0.95 | x | ND | ND |
| Adult 5 | 0.86 | 0.87 | x | x | x |
| Adult 6 | 0.95 | 0.84* | x | x | x |
| Adult 7 | 0.98 | 0.99 | x | x | x |
| Adult 8 | 0.88 | 1.01 | x | x | x |
| Adult 9 | 0.81* | 1.07 | x | x | x |
| Adult 10 | 0.97 | 0.94 | x | ND | ND |
| Adult 11 | 0.79* | 0.92 | x | x | x |
| Adult 12 | 0.90 | 1.00 | ND | x | x |
| Adult 13 | 0.97 | 0.97 | x | x | x |
| Pediatric 1 | 0.93 | 1.03 | x | x | x |
| Pediatric 2 | 0.99 | 1.01 | x | x | x |
| Pediatric 3 | 0.88 | 0.94 | x | x | ND |
| Pediatric 4 | 1.00 | 0.91 | x | x | x |
| Pediatric 5 | 1.00 | 0.91 | x | x | x |
| Pediatric 6 | 0.94 | 1.00 | x | x | x |
| Pediatric 7 | 0.83* | 0.88 | x | ND | ND |
| No. | 20 | 20 | 19 | 15 | 14 |
| Mean | 0.92 | 0.96 | — | — | — |
| SEM | 0.02 | 0.01 | — | — | — |
Twenty Ficoll-purified primary AML cell samples were analyzed for viability, cholesterol content, LDLR and HMG-CoAR RNA levels in semiquantitative, multiplex RT-PCR and quantitative, real-time RT-PCR after cells were cultured for 18 to 24 hours with and without drug treatments (DNR, 0.05 μM; ARA-C, 0.2 μM). Viability data represent trypan blue-negative cell fractions and are expressed relative to untreated controls for each sample. The number of samples analyzed and the mean relative viabilities are shown, as are SEMs; x represents assays that were performed with individual AML samples (see data in Figure 2).
Via indicates viability; chol, cholesterol, Semi-Q, semiquantitative, multiplex RT-PCR; Quant, quantitative, real-time RT-PCR; and ND, assays not performed.
Indicates viabilities that were reduced more than 15% by drug treatments.